Impact News +++ Roblox to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 (Business Wire) +++ ROBLOX Aktie +3,94%

ANI PHARMA Aktie

>ANI PHARMA Aktienkurs

72.5 EUR +9.9% (Tradegate)

Ask: 72.5 EUR / 41 Stück

Bid: 72 EUR / 41 Stück

Tagesumsatz: 226 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ANI PHARMA Aktie über LYNX handeln

Intraday

1 Jahr

>ANI PHARMA Performance

1 Woche: +7,8%

1 Monat: +4,3%

3 Monate: -6,1%

6 Monate: +30,6%

1 Jahr: +34,9%

laufendes Jahr: +3,6%

>ANI PHARMA Aktie

Name:

ANI PHARMACEUT. DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US00182C1036 / A1W15D

Symbol/ Ticker:

BSFA (Frankfurt) / ANIP (NASDAQ)

Kürzel:

FRA:BSFA, ETR:BSFA, BSFA:GR, NASDAQ:ANIP

Index:

Webseite:

https://anipharmaceutical..

Profil:

Ani Pharmaceuticals Inc. is a specialty pharmaceut..
>Volltext..

Marktkapitalisierung:

1565.11 Mio. EUR

Unternehmenswert:

1872.59 Mio. EUR

Umsatz:

710.73 Mio. EUR

EBITDA:

124.49 Mio. EUR

Nettogewinn:

30.69 Mio. EUR

Gewinn je Aktie:

1.46 EUR

Schulden:

542.86 Mio. EUR

Liquide Mittel:

225.75 Mio. EUR

Operativer Cashflow:

146.74 Mio. EUR

Bargeldquote:

Umsatzwachstum:

41.25%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 133.653 USD.

Suchwörter:

ANI PHARMA, ANI PHARMACEUTICALS

Letzte Datenerhebung:

12.01.26

>ANI PHARMA Kennzahlen

Aktien/ Unternehmen:

Aktien: 22.46 Mio. St.

Frei handelbar: 86.26%

Leerverk. Aktien: 11.88%

Rückkaufquote: -0.18%

Mitarbeiter: 897

Umsatz/Mitarb.: 0.59 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 37.5%

Bewertung:

KGV: 48.58

KGV lG: 10.55

KUV: 2.09

KBV: 3.52

PEG-Ratio: -

EV/EBITDA: 15.04

Rentabilität:

Bruttomarge: 50.09%

Gewinnmarge: 4.32%

Operative Marge: 6.46%

Managementeffizenz:

Gesamtkaprendite: 2.65%

Eigenkaprendite: 7.83%

>ANI PHARMA Peer Group

Es sind 592 Aktien bekannt.

>ANI PHARMA Chart & Kurs - NASDAQ

>ANI PHARMA News

12.01.26 - 12:54

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities (GlobeNewswire EN)

PRINCETON, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced preliminary select financial results for full year 2025, provided full year 2026 financial guidance, and outlined its strategic priorities for continued growth. Nikhil Lalwani, ANI's President and Chief Executive Officer, will discuss these updates as part of a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT/6:00 p.m. ET....

06.01.26 - 22:18	ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
	PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET....

06.01.26 - 19:00	ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now? (Zacks)
	ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases....

23.12.25 - 16:42	ANI Pharma stock pullback tied to Cortrophin guidance uncertainty (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

22.12.25 - 16:00	3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 (Zacks)
	EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well....

20.12.25 - 03:01	Insiderhandel: SVP, CHIEF HR OFFICER verkauft Aktien von ANI Pharmaceuticals im Wert von 133653 USD (Insiderkauf)
	Davis, Krista - Vorstand - Tag der Transaktion: 2025-12-18...

13.12.25 - 03:01	Insiderhandel: SR. VP, GENERAL COUNSEL & SEC. verkauft Aktien von ANI Pharmaceuticals im Wert von 32928 USD (Insiderkauf)
	Cook, Meredith - Vorstand - Tag der Transaktion: 2025-12-12...

11.12.25 - 18:15	Implied Volatility Surging for ANI Pharmaceuticals Stock Options (Zacks)
	Investors need to pay close attention to ANIP stock based on the movements in the options market lately....

10.12.25 - 04:01	Insiderhandel: Aufsichtsrat verkauft Aktien von ANI Pharmaceuticals im Wert von 146070 USD (Insiderkauf)
	Tannenbaum, Renee P. - Aufsichtsrat - Tag der Transaktion: 2025-12-05...

02.12.25 - 12:54	ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise (GlobeNewswire EN)
	Expert retina and uveitis specialists will help support the growth and innovation of ANI's ophthalmology and retina franchise for a meaningful impact on patients Expert retina and uveitis specialists will help support the growth and innovation of ANI's ophthalmology and retina franchise for a meaningful impact on patients...

01.12.25 - 12:54	ANI Pharmaceuticals Announces Board Transition (GlobeNewswire EN)
	Patrick D. Walsh steps down as Chairman and will complete his current term as Board memberThomas J. Haughey has been unanimously elected to serve as the next Chairman of the Board...

28.11.25 - 18:15	ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? (Zacks)
	ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival....

25.11.25 - 12:54	ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire EN)
	PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, at 2:00 p.m. ET....

21.11.25 - 16:45	Here′s How ANIP′s Rare Disease Portfolio Is Driving Top-line Growth (Zacks)
	ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales....

18.11.25 - 17:42	Jefferies Konferenz: ANI Pharmaceuticals skizziert Wachstumsstrategie für seltene Krankheiten (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

18.11.25 - 04:02	Insiderhandel: Aufsichtsrat verkauft Aktien von ANI Pharmaceuticals im Wert von 750904 USD (Insiderkauf)
	Walsh, Patrick D. - Aufsichtsrat - Tag der Transaktion: 2025-11-13...

15.11.25 - 02:01	Insiderhandel: SR. VP, GENERAL COUNSEL & SEC. verkauft Aktien von ANI Pharmaceuticals im Wert von 34908 USD (Insiderkauf)
	Cook, Meredith - Vorstand - Tag der Transaktion: 2025-11-13...

15.11.25 - 02:01	Insiderhandel: SVP - CORP. DEV. & STRATEGY verkauft Aktien von ANI Pharmaceuticals im Wert von 1304163 USD (Insiderkauf)
	Gassert, Chad - Vorstand - Tag der Transaktion: 2025-11-12...

15.11.25 - 02:01	Insiderhandel: SVP - CORP. DEV. & STRATEGY verkauft Aktien von ANI Pharmaceuticals im Wert von 8272 USD (Insiderkauf)
	Gassert, Chad - Vorstand - Tag der Transaktion: 2025-11-13...

14.11.25 - 16:00	ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? (Zacks)
	ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Augen sehen nicht die Wimpern. - Sprichwort China

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram